Molecular modelling of CYP3A4 from an alignment with CYP102: Identification of key interactions between putative active site residues and CYP3A-specific chemicals

Xenobiotica

Volumn 26, Issue 10, 1996, Pages 1067-1086

  Lewis, D F V ^a   Eddershaw, P J ^b   Goldfarb, P S ^a   Tarbit, M H ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DAPSONE; ERYTHROMYCIN; FLUTICASONE PROPIONATE; GESTODENE; GR 54374; GRANISETRON; KETOCONAZOLE; NARATRIPTAN; NIFEDIPINE; OMEPRAZOLE; ONDANSETRON; QUINIDINE; SALMETEROL; SAPRISARTAN; TAMOXIFEN; TESTOSTERONE; UNCLASSIFIED DRUG; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE;

AMINO ACID SEQUENCE; ARTICLE; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; HYDROXYLATION; LIVER MICROSOME METABOLISM; MOLECULAR MODEL;

BACTERIA (MICROORGANISMS);

EID: 0029805701     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609167423     Document Type: Article

References (52)

1. ANDERSSON, T., MINERS, J. O., VERONSE, M. E., TASSANEEYAKUL, W., MEYEK, U. A., and BIRKETT, D. J., 1993, Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. British Journal of Clinical Pharmacology, 36, 521-530.
2. BEAUNE, P. H., UMBENHAUER, D. R., BORK, R. W., LLOYD, R. S., and GUENGERICH, F. P., 1986, Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. Proceedings of the National Academy of Sciences, USA, 83, 8064-8068.
3. BLOOMER, J. C., BALDWIN, S. J., SMITH, G. J., AYRTON, A D., CLARKE, S. E., and CHENERY, R. J., 1994, Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. British Journal of Clinical Pharmacology, 38, 557-566.
4. BORK, R. W., MUTO, T., BEAUNE, P. H., SRIVASTAVA, P. K., LLOYD, R. S., and GUENGERICH, F. P., 1989, Characterisation of mRN A species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. Journal of Biological Chemistry, 264, 910-919.
5. DEGTYARENKO, K. N. and ARCHAKOV, A. I., 1993, Molecular evolution of P450 superfamily and P450-containing monoxygenase systems. FEBS Letters, 332, 1-8.
6. DE LEMOS-CHIARANDINI, C., FREY, A. B., SABATININI, D. D , and KREIBICH, G., 1987, Determination of the membrane topology of the phenobarbital-inducible rat liver cytochrome P-450 isoenzyme PB-4 using site-specific antibodies. Journal of Cell Biology, 104, 209-219.
7. EATON, D. L. and GALLAGHER, E. P., 1994, Mechanisms of aflatoxin carcinogenesis. Annual Review of Pharmacology and Toxicology, 34, 135-172.
8. FERENCZY, G. G. and MORRIS, G. M., 1989, The active site of cytochrome P-450 nifedipine oxidase: a model-building study. Journal of Molecular Graphics, 7, 206-211.
9. FISCHER, V., VICKERS, A. E. M., HEITZ, F., MAHADEVAN, S., BALDECK, J. P., MINERY, P., and TYNES, R., 1994, The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metabolism and Disposition, 22, 269-274.
10. GONZALEZ, F. J., 1992, Human cytochromes P450: problems and prospects. Trends in Pharmaceutical Sciences, 13, 346-352.
11. GONZALEZ, K. J. and GELBOIN, H. V., 1994, Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metabolism Reviews, 26, 165-183.
12. GUENGERICH, F. P., 1994, Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicology Letters, 70, 133-138.
13. GUENGERICH, F. P. and SHIMADA, T., 1991, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology, 4, 391-407.
14. GUENGERICH, F. P., SHIMADA, T., RANEY, K. D., YUN, C.-H., MEYER, D. J., KETTERER, B., HARRIS, T. M., GROOPMAN, J. D., and KADLUBAR, F. F., 1992, Elucidation of catalytic specificities of human cytochrome P450 and glutathione S-transferase enzymes and relevance to molecular epidemiology. Environmental Health Perspectives, 98, 75-80.
15. HALPERT, J. R-, GUENGERICH, F. P., BEND, J. R., and CORREIA, M. A., 1994, Selective inhibitors of cytochromes P450. Toxicology and Applied Pharmacology, 125, 163-175.
16. HASEMANN, C. A., KURUMBAIL, R. G., BODDUPALLI, S. S., PETERSON, J. A., and DEISENHOFER, J., 1995, Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure, 3, 41-62.
17. HUNT, C. M., WATKINS, P. B., SAENGER, P., STAVE, G. M., BARLASCINI, N., WATLINGTON, C. O., WRIGHT, J. T., and GUZELIAN, P. S., 1992, Heterogeneity of CYP3A isoforms metabolising erythromycin and cortisol. Clinical Pharmacology and Therapeutics, 51, 18-23.
18. JACOLOT F., SIMON, I., DREANO, Y., BEAUNE, P., RICHE, C., and BERTHOU, F., 1991, Identification of the cytochrome P450IIIA family and the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochemical Pharmacology, 41, 1911-1919.
19. KOLEV, A. P., BUTERS, J. T. M., ROBINSON, R. C., MARKOWITZ, A., and FRIEDMAN, F. K., 1995, CO binding kinetics of human cytochrome P450 3A4. Journal of Biological Chemistry, 270, 5014-5018.
20. KORZEKWA, K. R. and JONES, J. P., 1993, Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics, 3, 1-18.
21. KRONBACH, T., FISCHER, V., and MEYER, U.A., 1988, Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolising enzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics, 43, 630-635.
22. LAKE, B. G. and LEWIS, D. F. V., 1996, The CYP4 family. In Cytochromes P450: Metabolic and Toxicological Aspects, edited by C. Ioannides (Boca Raton: CRC Press), pp. 269-295.
23. LEEDER, J. S., GAEDIGK, A., LU, X., and COOK, V. A., 1994, Characterisation of the human anti-cytochrome P450 antibody response in hypersensitivity reactions to aromatic anticonvulsants, Proceedings of the 10th International Symposium on Microsomes and Drug Oxidations, July 18-21, Toronto, Canada, pp. 161-163.
24. LEWIS, D. F. V., 1995, Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). Xenobiotica, 25, 333-366.
25. LEWIS, D. F. V., 1996a, Cytochromes P450: Structure, Function and Mechanism (London: Taylor & Francis).
26. LEWIS, D. F. V., 1996b, Molecular modelling of mammalian cytochromes P450 with specific substrates and inhibitors. In Cytochromes P450: Metabolic and Toxicological Aspects, edited by C. Ioannides (Boca Raton: CRC Press), pp. 353-389.
27. LEWIS, D. F. V. and LAKE, B. G., 1995, Molecular modelling of members of the P4502A subfamily: application to studies of enzyme specificity. Xenobiotica, 25, 585-598.
28. LEWIS, D. F. V., LAKE, B. G., and PARKE, D. V., 1995, Molecular orbital-generated QSARs in an homologous series of alkoxyresorufins and studies of their interative docking with cytochromes P450. Xenobiotica, 25, 1355-1369.
29. LEWIS, D. F. V., MOEREELS, H., LAKE, B. G., IOANNIDES, C., and PARKE, D. V., 1994, Molecular modelling of enzymes and receptors involved in carcinogenesis: QSARs and COMPACT-3D. Drug Metabolism Reviews, 26, 261-285.
30. LINDBERG, R. L. P. and NEGISHI, M., 1989, Alteration of mouse cytochrome P450 substrate specificity by mutation of single amino-acid residue. Nature, 339, 632-634.
31. MAENPAA, J., PELKONEN, O., CRESTEIL, T., and RANE, A., 1993, The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. Journal of Steroid Biochemistry and Molecular Biology, 44, 61-67.
32. MANCHEE, G. R., EDDERSHAW, P. J., RANSHAW, L. E., HERRIOTT, D., PARK, G. R., BAYLISS, M. K., and TARBIT, M. H., 1996, The aliphatic oxidation of salmeterol to α-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A. Drug Metabolism and Disposition, 24, 555-559.
33. cam research. In Cytochrome P450, edited by P. R. Ortiz de Montellano (New York: Plenum), pp. 83-124.
34. NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, R., GONZALEZ, F. J., COON, M. J., GUNSALUS, I. C., GOTOH, O., OKUDA, K., and NEBERT, D. W., 1993, The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names and nomenclature. DNA and Cell Biology, 12, 1-51.
35. NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., ESTABROOK, R. W., GUNSALUS, I. C., and NEBERT, D. W., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
36. PAULSEN, M. D. and ORNSTEIN, R. L., 1995, Dramatic differences in the motions of the mouth of open and closed cytochrome P450BM-3 by molecular dynamics simulations. Proteins: Structure, Function and Genetics, 21, 237-243.
37. POULOS, T. L., 1988, Cytochrome P450: molecular architecture, mechanism, and prospects for rational inhibitor design. Pharmaceutical Research, 5, 67-75.
38. POULOS, T. L., 1996, Ligands and electrons and haem proteins. Nature and Structural Biology, 3, 401-403.
39. cam. Biochemistry, 26, 8165-8174.
40. cam: crystallography, oxygen activation, and electron transfer. FASEB Journal, 6, 674-679.
41. cam ternary complex. Biochemistry, 28, 7586-7592.
42. RAVICHANDRAN, K. G., BODDUPALLI, S. S., HASEMAN, C. A., PETERSON, J. A., and DEISENHOFER, J., 1993, Crystal structure of hemoprotein domain of P450 BM-3, a prototype for microsomal P450s. Science, 261, 731-736.
43. SHIMADA, T., ZAMAZAKI, H., MIMURA, M., INUI, Y., and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
44. SHOU, M., GROGAN, J., MANCEWICZ, J. A., KRAUSZ, K. W., GONZALEZ, F. J., GELBOIN, H. V., and KORZEKWA, K. R., 1994, Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry, 33, 6450-6455.
45. SMITH, D. A., 1991, Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metabolism Reviews, 23, 355-373.
46. SMITH, D. A. and JONES, B. C., 1992, Speculations on the substrate structure - activity relationship (SSAR) of cytochrome P450 enzymes. Biochemical Pharmacology, 44, 2089-2098.
47. SPATZENEGGER, M. and JAEGGER, W., 1995, Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews, 27, 397-417.
48. cam (CYP101) F87W and F87A mutants. Journal of Biological Chemistry, 268, 269-275.
49. VON WACHENFELDT, C. and JOHNSON, E. F., 1995, Structures of eukaryotic cytochrome P450 enzymes. In Cytochrome P450, edited by P. R. Ortiz de Montellano (New York: Plenum), pp. 183-223.
50. WATKINS, P. B., 1990, Role of cytochromes P450 in drug metabolism and hepatotoxicity. Seminars in Liver Disease, 10, 235-250.
51. WAXMAN, D. J., LAPENSON, D. P., AOYAMA, T., GELBOIN, H. V., GONZALEZ, F. J., and KORZEKWA, K., 1991, Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Archives of Biochemistry and Biophysics, 290, 160-166.
52. WRIGHTON, S. A., and STEVENS, J. C., 1992, The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicology, 22, 1-21.